Leadership

Jeffrey Bluestone, Ph.D. is one of the leading immunologists in the field of T-cell activation and immune tolerance research that has led to the development of multiple immunotherapies, including the first FDA-approved drug targeting T-cell co-stimulation to treat autoimmune disease and organ transplantation and the first CTLA-4 antagonist drugs approved for the treatment of metastatic melanoma.

Dr. Bluestone is an academic leader on a national and international scale. He is former President and CEO of the Parker Institute for Cancer Immunotherapy, and was the founding director of the Immune Tolerance Network, the largest NIH-funded multicenter clinical immunology research program, testing novel immunotherapies in transplantation, autoimmunity and asthma/allergy.  While holding the A.W. and Mary Margaret Clausen Distinguished Professorship at UCSF, Dr. Bluestone also served as executive vice chancellor and provost emeritus at UCSF and was the former director of the UCSF Diabetes Center.

Dr. Bluestone has received numerous awards including: a Guggenheim Fellowship; election to the American Academy of Arts and Sciences; the National Academy of Medicine; and the National Academy of Sciences; and an appointed member of Vice President Joe Biden’s Cancer Moonshot Blue Ribbon Panel.

Fred Ramsdell, Ph.D., is a veteran biotechnology leader in immunology with nearly three decades of experience. Fred is a founder of Sonoma and serves at the Chief Scientific Officer. Immediately prior to Sonoma, Fred was the CSO at the Parker Institute for Cancer Immunotherapy (PICI) where he helped to build and advance multiple research programs from the inception of the Institute.

After a fellowship at the NIH, Fred joined Immunex studying T cell activation and tolerance, with a focus on gene discovery and functional characterization. He later joined Darwin Molecular (which was later acquired by Celltech R&D) to establish the immunology program. Amongst other programs, he led the team that discovered and characterized FoxP3, a gene critical to the function of regulatory T-cells. Fred joined ZymoGenetics in 2004, where he led teams studying novel proteins with potential regulatory activity in lymphoid cells. In 2008, Novo Nordisk brought Dr. Ramsdell on to help establish the company’s new Inflammation Research Center in Seattle and lead the Immunobiology group.

He earned his doctoral degree in microbiology and immunology from the University of California, Los Angeles and holds a bachelor’s degree in biochemistry and cell biology from the University of California, San Diego.

Doug Sheehy is a senior biotechnology executive who has managed global legal and compliance operations for multiple companies. Prior to joining Sonoma, Sheehy served as General Counsel and Secretary for Aimmune Therapeutics, Inc., a publicly traded biopharmaceutical company that develops and commercializes treatments for potentially life-threatening food allergies. Aimmune’s lead product, PALFORZIA®, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of peanut allergy in 2020. Aimmune was acquired by Nestle Health Science for $2.6 billion in late 2020. Sheehy previously served as Executive Vice President, Chief Administrative Officer, General Counsel and Secretary of Codexis, Inc., a publicly traded biotechnology company that develops novel treatments for rare diseases and industrial synthetic enzymes for the pharmaceutical and food industries. Prior to Codexis, Sheehy served as Executive Director, Legal at CV Therapeutics, Inc., a publicly traded biopharmaceutical company that developed and commercialized treatments for cardiovascular disease. He started his career as a corporate and securities lawyer in Silicon Valley representing emerging growth companies and venture funds at Gunderson Dettmer.

Sheehy received an A.B. in History from Dartmouth College and a J.D. from American University’s Washington College of Law, where he was Editor-in-Chief of the American University Law Review.

An accomplished biotechnology executive, Peter DiLaura has nearly 25 years of experience in corporate development, strategy, and business leadership. He joined the company in 2020 from Third Rock Ventures, where he served as an Entrepreneur-in-Residence, focused on building innovative therapeutic companies. Prior to Third Rock, Peter spent five years as the Chief Executive Officer of Second Genome, a therapeutics company developing novel drugs from microbiome science. Earlier in his career, Peter led all corporate development at Ingenuity Systems, a systems biology company.  Peter began his career in life sciences as a consultant in the New York office of The Wilkerson Group.

Peter holds a BS in Economics from the Wharton School of the University of Pennsylvania.

At Sonoma Biotherapeutics, Peter is responsible for corporate development, strategic planning, and operations.

Jessica Stitt, MBA is a global biotech financial executive with over 20 years of experience in corporate transactions, healthcare finance and strategy. She most recently served as Chief Financial Officer at Gyroscope Therapeutics, a global clinical-stage gene therapy company focused on disease of the eye, acquired by Novartis. Prior to Gyroscope, Stitt served as Vice President of Finance and Operations for MyoKardia, Inc., a biopharmaceutical company developing targeted therapies for the treatment of serious cardiovascular diseases, acquired by Bristol Myers Squibb. She served as Vice President of Finance and Investor Relations for Theravance Biopharma, Inc., after the company’s spin-off from Theravance, Inc., now Innoviva, Inc. She previously held roles in finance at Nektar Therapeutics, Alkermes and Blue Cross Blue Shield of Massachusetts.

Stitt holds an MBA from Simmons School of Management and a B.A. from Saint Anselm College.

John Davis, M.D., MPH, M.S., is an experienced physician-scientist drug developer and biotechnology executive with deep expertise across multiple platforms, technologies, and therapeutic areas. He has a passion for developing novel therapeutics to improve the lives of patients and a track record of success in strategic leadership, global development, and regulatory strategy across multiple therapeutic areas in biotechnology, mid-size and large pharmaceutical, and academic settings for nearly 30 years.

Dr. Davis serves on the board of directors at Sonoma Bio and is Chair of the Science Committee. He previously served on the board of directors at Rheos Medicines and is a strategic advisor and member of the Scientific Advisory Board at HIBio Therapeutics and Oak Hill Bio. He is President of Norte Health Consulting. He is also an attending volunteer physician at the Boston VA Medical Center Rheumatology Clinic.

Previous roles include Head of Research and Development/Chief Medical Officer and Member of the Scientific Advisory Board at Magenta Therapeutics; Senior Vice President of Early Clinical Development at Pfizer; Global Head of Immunology and Vice President at Baxalta (Acquired by Shire), Therapeutic Area Head and Senior Group Director Inflammation, Cardiovascular/Metabolism gRED at Genentech, and Professor of Clinical Medicine and Director of Clinical Research Center, Lupus Clinic, and Spondylitis Clinic at UCSF.

Dr. Davis earned an MD from the University of Maryland, an M.P.H. in Epidemiology from the UC Berkeley, and an MS in Anatomy from the University of Maryland. He trained in Internal Medicine and Rheumatology/Autoimmune Disease at UCSF and NIH. He is a Fellow in both the American College of Physicians and the American College of Rheumatology. He has authored over 120 publications and book chapters and has held international leadership positions in his areas of research focus in autoimmune disease.